Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems • Medical Devices & Mechanical Engineering
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Sungkwang Medical Foundation currently faces 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners. The portfolio is spread across 5 distinct art units, indicating a diverse range of technical subject matter within the life sciences. LULTSCHIK, WILLIAM G is the busiest examiner for the foundation. This examiner is currently managing 1 busiest examiner pending action. The ratio of 5 pending office actions to 5 distinct examiners shows that no single examiner is handling more than one case.
This distribution across 5 distinct art units suggests that the foundation's patent applications are being reviewed by several different specialized groups. LULTSCHIK, WILLIAM G, despite being the busiest, only holds 1 busiest examiner pending action. This suggests a broad but thin distribution of work across the USPTO. Practitioners should note that the Biotechnology & Pharmaceuticals technology area is being examined across 5 distinct art units, requiring a strategy that addresses many different specialized groups.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (40%) |
| §112 only | 2 (40%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LULTSCHIK, WILLIAM G | 1 | 22.3% | +31.3% |
| JANG, CHRISTIAN Y | 1 | 68.5% | +21.0% |
| NGUYEN, NGHI V | 1 | 53.6% | +50.8% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.9% |
| REGLAS, GILLIAN CHELSEA | 1 | 30.2% | +41.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556783 | MESENCHYMAL STEM CELLS HAVING ENHANCED OSTEOGENIC DIFFERENTIATION CAPACITY, AND USE THEREOF | NGUYEN, NGHI V | 28d overdue |
| 19127953 | SERVER FOR AUTOMATICALLY DIAGNOSING MALE INFERTILITY, AND METHOD FOR DIAGNOSING MALE INFERTILITY BY USING SAME | LULTSCHIK, WILLIAM G | — |
| 18264521 | METHOD FOR DIFFERENTIATING PLURIPOTENT STEM CELL-DERIVED HEMOGENIC ENDOTHELIAL CELLS INTO LYMPHOID LINEAGE CELLS | WILSON, MICHAEL C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18556783 | MESENCHYMAL STEM CELLS HAVING ENHANCED OSTEOGENIC DIFFERENTIATION CAPACITY, AND USE THEREOF | NGUYEN, NGHI V | 28d overdue |
| 19127953 | SERVER FOR AUTOMATICALLY DIAGNOSING MALE INFERTILITY, AND METHOD FOR DIAGNOSING MALE INFERTILITY BY USING SAME | LULTSCHIK, WILLIAM G | — |
| 18846979 | METHOD FOR PROVIDING FETUS MONITORING SERVICE AND SERVER FOR PERFORMING SAME | JANG, CHRISTIAN Y | — |
| 18264521 | METHOD FOR DIFFERENTIATING PLURIPOTENT STEM CELL-DERIVED HEMOGENIC ENDOTHELIAL CELLS INTO LYMPHOID LINEAGE CELLS | WILSON, MICHAEL C | — |
| 17296137 | A COMPOSITION COMPRISING MESENCHYMAL STEM CELLS FOR INHIBITING ADIPOGENESIS | REGLAS, GILLIAN CHELSEA | — |
| Art Unit | Apps |
|---|---|
| 3682 | 1 |
| 3796 | 1 |
| 1653 | 1 |
| 1638 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19127953 | SERVER FOR AUTOMATICALLY DIAGNOSING MALE INFERTILITY, AND METHOD FOR DIAGNOSING MALE INFERTILITY BY USING SAME | LULTSCHIK, WILLIAM G | 3682 | §101§103 | Non-Final OA | — | Pending | Aug 29, 2025 |
| 18846979 | METHOD FOR PROVIDING FETUS MONITORING SERVICE AND SERVER FOR PERFORMING SAME | JANG, CHRISTIAN Y | 3796 | §112 | Non-Final OA | — | Pending | Sep 13, 2024 |
| 18556783 | MESENCHYMAL STEM CELLS HAVING ENHANCED OSTEOGENIC DIFFERENTIATION CAPACITY, AND USE THEREOF | NGUYEN, NGHI V | 1653 | §101§103 | Final Rejection | 28d overdue | Pending | Oct 23, 2023 |
| 18264521 | METHOD FOR DIFFERENTIATING PLURIPOTENT STEM CELL-DERIVED HEMOGENIC ENDOTHELIAL CELLS INTO LYMPHOID LINEAGE CELLS | WILSON, MICHAEL C | 1638 | §103§112 | Final Rejection | — | Pending | Aug 07, 2023 |
| 17296137 | A COMPOSITION COMPRISING MESENCHYMAL STEM CELLS FOR INHIBITING ADIPOGENESIS | REGLAS, GILLIAN CHELSEA | 1632 | §112 | Final Rejection | — | Pending | May 21, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial